Surmodics

Abbott and Surmodics announced an agreement for Abbott to have exclusive worldwide commercialization rights for Surmodics' SurVeil drug-coated balloon to treat the superficial femoral artery. Abbott also received options for below-the-knee and AV fistula drug-coated balloon products.

Abbott and Surmodics entered an agreement granting Abbott exclusive worldwide commercialization rights for Surmodics' SurVeil drug-coated balloon, with collaboration on development, clinical trials, and regulatory activities for U.S. and European approval.